Continental Building (CBPX) Received Barclays Higher Rating; Last Week Acceleron Pharma Inc. (XLRN) Coverage

January 5, 2018 - By Hazel Jackson

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 69% are positive. Acceleron Pharma had 34 analyst reports since August 13, 2015 according to SRatingsIntel. As per Thursday, June 1, the company rating was maintained by Oppenheimer. The firm earned “Outperform” rating on Monday, January 18 by FBR Capital. On Thursday, August 13 the stock rating was initiated by Morgan Stanley with “Overweight”. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Outperform” rating given on Tuesday, December 13 by Oppenheimer. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Hold” rating by Oppenheimer on Friday, June 23. As per Monday, June 13, the company rating was maintained by Barclays Capital. The rating was maintained by UBS with “Buy” on Tuesday, September 12. The rating was initiated by Oppenheimer with “Outperform” on Friday, November 20. On Wednesday, September 20 the stock rating was maintained by Barclays Capital with “Overweight”. Piper Jaffray maintained Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Friday, October 6. Piper Jaffray has “Buy” rating and $40.0 target. See Acceleron Pharma Inc. (NASDAQ:XLRN) latest ratings:

14/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: $35 New Target: $51 Maintain
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $44.0 Maintain
12/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $57 Initiates Coverage On
06/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $40.0 Maintain
21/09/2017 Broker: Credit Suisse Rating: Hold New Target: $35.0 Downgrade
20/09/2017 Broker: Barclays Capital Rating: Overweight Old Target: $42 New Target: $50 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Sector Perform New Target: $44 Initiates Coverage On
12/09/2017 Broker: UBS Rating: Buy New Target: $50.0 Maintain
04/08/2017 Broker: Credit Suisse Rating: Buy New Target: $35.0000
04/08/2017 Broker: Citigroup Rating: Buy New Target: $44.0000

Among 10 analysts covering Continental Building Products (NYSE:CBPX), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Continental Building Products has $30.0 highest and $17 lowest target. $26.14’s average target is -8.12% below currents $28.45 stock price. Continental Building Products had 27 analyst reports since August 23, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Monday, October 12 by BB&T Capital. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, February 23. Citigroup maintained Continental Building Products, Inc. (NYSE:CBPX) rating on Monday, April 18. Citigroup has “Neutral” rating and $21 target. The company was maintained on Monday, May 16 by Deutsche Bank. The stock of Continental Building Products, Inc. (NYSE:CBPX) earned “Hold” rating by Deutsche Bank on Tuesday, November 17. As per Tuesday, October 13, the company rating was maintained by Barclays Capital. The stock of Continental Building Products, Inc. (NYSE:CBPX) has “Buy” rating given on Monday, November 16 by Sterne Agee CRT. The firm has “Neutral” rating by Seaport Global Securities given on Tuesday, November 22. RBC Capital Markets maintained Continental Building Products, Inc. (NYSE:CBPX) on Wednesday, May 11 with “Outperform” rating. The firm has “Outperform” rating given on Monday, November 2 by RBC Capital Markets.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $1.94 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Investors sentiment increased to 1.81 in Q3 2017. Its up 0.37, from 1.44 in 2017Q2. It is positive, as 12 investors sold Acceleron Pharma Inc. shares while 30 reduced holdings. 30 funds opened positions while 46 raised stakes. 37.73 million shares or 12.48% more from 33.54 million shares in 2017Q2 were reported. Geode Cap Ltd Liability accumulated 322,834 shares or 0% of the stock. Eagle Asset Mgmt holds 0.27% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 1.25M shares. Moreover, Cornerstone Capital Mngmt Holdg Lc has 0.01% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 20,883 shares. Alliancebernstein Ltd Partnership has 43,150 shares. Trexquant Invest Lp accumulated 7,120 shares or 0.07% of the stock. Jpmorgan Chase Co reported 91,900 shares stake. Maryland-based Proshare Advisors Ltd Liability has invested 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN). Raymond James Assoc reported 8,586 shares stake. Cubist Systematic Strategies Llc reported 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Hillhouse Capital Management Ltd reported 700,000 shares or 0.43% of all its holdings. Sg Americas Ltd Limited Liability Company holds 0% or 12,239 shares in its portfolio. Barclays Plc owns 7,944 shares for 0% of their portfolio. Eam Invsts Ltd Liability Corporation reported 56,427 shares. Retail Bank Of America De has 97,468 shares for 0% of their portfolio. Alps Advsrs invested in 0.01% or 38,027 shares.

The stock decreased 3.29% or $1.46 during the last trading session, reaching $42.94. About 332,656 shares traded or 8.96% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has declined 22.43% since January 5, 2017 and is downtrending. It has underperformed by 39.13% the S&P500.

Since August 8, 2017, it had 1 buy, and 7 selling transactions for $21.12 million activity. On Tuesday, September 12 the insider Quisel John D sold $196,423. $706,799 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Sherman Matthew L on Tuesday, September 12. $614,546 worth of stock was sold by MCLAUGHLIN KEVIN F on Tuesday, September 12. The insider Rovaldi Christopher sold $537,786. 105,122 Acceleron Pharma Inc. (NASDAQ:XLRN) shares with value of $3.76 million were sold by George Jean. Shares for $196,418 were sold by Kumar Ravindra on Tuesday, September 12. CELGENE CORP /DE/ had bought 745,592 shares worth $27.59M on Monday, September 25.

Continental Building Products, Inc. makes and sells gypsum wallboard and complementary finishing products in the eastern United States and eastern Canada. The company has market cap of $1.07 billion. The firm sells its products to gypsum wallboard distributors, buying groups, wholesalers, and mass merchants in the new residential, repair and remodel, and commercial construction markets under the LiftLite, Mold Defense, and Weather Defense names. It has a 23.3 P/E ratio.

Analysts await Continental Building Products, Inc. (NYSE:CBPX) to report earnings on February, 22. They expect $0.32 EPS, up 3.23% or $0.01 from last year’s $0.31 per share. CBPX’s profit will be $12.07 million for 22.23 P/E if the $0.32 EPS becomes a reality. After $0.29 actual EPS reported by Continental Building Products, Inc. for the previous quarter, Wall Street now forecasts 10.34% EPS growth.

Investors sentiment decreased to 1.06 in 2017 Q3. Its down 0.24, from 1.3 in 2017Q2. It worsened, as 17 investors sold Continental Building Products, Inc. shares while 49 reduced holdings. 25 funds opened positions while 45 raised stakes. 35.06 million shares or 5.09% less from 36.94 million shares in 2017Q2 were reported. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta invested in 0.02% or 74,500 shares. Pacad Inv Limited stated it has 6,000 shares. American Grp Inc reported 26,498 shares stake. Trexquant Investment Limited Partnership stated it has 0.09% of its portfolio in Continental Building Products, Inc. (NYSE:CBPX). California State Teachers Retirement System holds 63,101 shares or 0% of its portfolio. State Street Corporation owns 773,337 shares. First Tru Advsrs Ltd Partnership holds 0% of its portfolio in Continental Building Products, Inc. (NYSE:CBPX) for 28,707 shares. First Quadrant L P Ca stated it has 0.05% of its portfolio in Continental Building Products, Inc. (NYSE:CBPX). Kennedy Cap Mgmt Inc has invested 0.01% in Continental Building Products, Inc. (NYSE:CBPX). Brinker stated it has 0.04% in Continental Building Products, Inc. (NYSE:CBPX). Westwood Gru Incorporated has invested 0.19% in Continental Building Products, Inc. (NYSE:CBPX). Prelude Capital Lc reported 4,425 shares stake. The New York-based New York State Teachers Retirement System has invested 0% in Continental Building Products, Inc. (NYSE:CBPX). Guyasuta Invest Advsrs Inc invested in 0.17% or 53,770 shares. Cubist Systematic Strategies Limited Liability holds 1,858 shares.